C. Difficile

An interview with the Rebiotix founder on the microbiota-based therapy and the newest preliminary pivotal phase 3 findings.

Before undergoing fecal microbiota transplant, “patients deserve risk mitigation, which can be accomplished with thorough vetting and regulation,” the authors of a new paper wrote.

Community-acquired infections—including those associated with outpatient settings—are still problematic, authors say.

After the MODIFY trial, investigators wanted to explore how bezlotoxumab treated patients in the real world.

Results from England’s first licensed FMT stool bank are now available.

An electronic alert that aids in diagnostic stewardship may be helpful in reducing inappropriate testing for C diff, according to a new study.

Using enteral vancomycin for C diff prophylaxis may be the key to reducing morbidity and improving outcomes in pediatric and young adult recipients of HSCT.

System hospitals are proactive in reducing incidence of C diff infections and CLABSIs, according to study in JAMA Network Open.

The new C diff strain may turn out to be particularly severe and requires sufficient monitoring.

Rebiotix has announced that it has completed enrollment of a phase 3 clinical trial for RBX2660.

Treatment with bezlotoxumab resulted in a statistically significant reduction of recurrent C diff in cancer patients, according to a new study.

Infection with C diff can increase hospital length of stay between 3 and 21 days, new research says.

A significant relationship exists between environmental exposures and colonization.

Some asymptomatic carriers of C diff went on to have clinical infection themselves within a 6-month period.

A team of investigators set out to identify whether a risk prediction model that was developed at Novant Health could accurately identify individuals at a high-risk for health care-associated C diff infection.

Prior to this study’s publication, the literature about pediatric C diff infection was limited.

The quick Pitt Bacteremia Score offers accuracy comparable to the original version's across multiple infections, and maintains ease of use.

Bezlotoxumab, a human monoclonal anti­body directed against Clostridioides diffi­cile toxin B, is currently indicated for the prevention of recurrent C diffi­cile infection

In 2017, a guideline update stripped metronidazole of its first-line therapy designation and crowned oral vancomycin as initial therapy for all C difficile infection cases.

DNA methyltransferase, an epigenetic process, has been found to mediate sporulation and pathogenesis in C diff.

The CDC’s plan calls for 30% reduction in C diff infections, but work remains to be done.

An observational study suggests that oral vancomycin may be associated with earlier symptom resolution than metronidazole for children hospitalized with non-severe C diff infections.

Agency’s annual report on healthcare-associated bugs highlights reduced incidence of CLABSI, CAUTI, and C diff.

Rates of health care facility-acquired C diff seemed to show improvement, but understanding community-acquired cases better in the future can help aid prevention efforts.

After receiving FMT capsules containing drug resistant ESBL E coli, 2 patients developed severe illness with 1 patient death.

Eravacycline may be an option for patients with a history of C diff or those with a history of infections who are at risk for developing the infection.

When guidelines are quickly implemented for C diff treatment recommendations, the changes are reflected quickly.

Use of high-risk antibiotics is linked to C diff infections, but the class of antibiotics with the strongest link has changed over time underscoring the need for ongoing assessment.

A hospital sheds light on how dogs can help identify C diff contamination.

Can UV disinfecting lights tackle health care-associated infections?